Figure 7
Antitumor effect of OAVs expressing scIL-12 variants. Syrian hamsters bearing intrahepatic HaP-T1 tumors were treated with a single local administration of the indicated OAVs at 2.5 × 108 i.u. (a) or 1 × 109 i.u. per hamster (b). The same model was used to evaluate the effect of OAV-scIL-12-TM upon intravenous administration (c) at the indicated doses. In all cases, hamsters were killed 4 weeks after the initiation of treatment and tumor volumes were measured at necropsy. Individual tumor volumes and group medians are represented. Note that values from animals that did not survive at this point as a result of scIL-12 toxicity were not included in this graph. *P<0.05.
